Ranbaxy Gets U.S. FDA Nod For Imitrex After Four Months Of Waiting
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Four months after the U.S. FDA imposed an import alert on 33 products manufactured by Ranbaxy, the company received a much needed shot in the arm after the drug regulator approved launch of its generic versions of GlaxoSmithKline's migraine drug Imitrex (sumatriptan) 100 mg, which has sales of over $1.1 billion in the U.S. alone
You may also be interested in...
Ranbaxy Sees Better Days Ahead With The Launch Of Valtrex Generic In U.S.
MUMBAI - There is finally some positive news for India's Ranbaxy as it launched the generic versions of GlaxoSmithKline's herpes treatment Valtrex (valacyclovir) Nov. 25 in the U.S
Ranbaxy Sees Better Days Ahead With The Launch Of Valtrex Generic In U.S.
MUMBAI - There is finally some positive news for India's Ranbaxy as it launched the generic versions of GlaxoSmithKline's herpes treatment Valtrex (valacyclovir) Nov. 25 in the U.S
U.S. FDA Nails Ranbaxy On Charges Of Falsifying Data; Halts All Application Reviews From Paonta Sahib Plant
MUMBAI - India's largest drug maker Ranbaxy received a body blow after the U.S. Food and Drug Administration initiated a new regulatory action against the company's Paonta Sahib-based manufacturing plant in India. The drug regulator halted review of drug applications from the manufacturing plant due to evidence of falsified data and invoked the Application Integrity Policy